

RECEIVED
CENTRAL FAX CENTER

MAR 27 2006

WORKMAN NYDEGGER
A PROFESSIONAL CORPORATION
ATTORNEYS AT LAW
1000 EAGLE GATE TOWER
60 EAST SOUTH TEMPLE
SALT LAKE CITY, UTAH 84111
TELEPHONE (801) 533-9800
FAX (801) 328-1707

TELECOPIER COVER SHEETMarch 27, 2006Total Number of Pages
(including cover letter): 11

Please deliver the transmitted facsimile pages to:

MAIL STOP AMENDMENT
ART UNIT 1614

Business Phone

Telecopier Phone: (571) 273-8300

From: JOHN M. GUYNN

Comments: Serial No. 10/816,571

Please see attached.

Docket No.: 15070.6.2

We are transmitting from a Sharp FO-750 or Sharp FO-6100 facsimile machine. If you do not receive all the pages or they are unreadable, please contact me as soon as possible at (801) 533-9800.

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS ATTORNEY PRIVILEGED AND CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

SJP0000001744V001

FILED VIA FACSIMILE

PATENT APPLICATION
Docket No.: 15070.6.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER
MAR 27 2006

In re application of:

B. Ron Johnson

Serial No.: 10/816,571

Confirmation No.: 1232

Filed: April 1, 2004

For: ANTI-INFECTIVE COMPOSITIONS, METHODS
AND SYSTEMS FOR TREATING PATHOGEN-
INDUCED DISORDERED TISSUES

Examiner: Not yet known

Customer No.: 022913

CERTIFICATE OF FACSIMILE TRANSMISSIONMail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

I hereby certify that this paper is being transmitted via facsimile at facsimile number (801) 328-1707 to the Patent and Trademark Office to phone no. (571) 273-8300 (Formal Fax No.) on the date shown below.

Date of deposit: March 27, 2006.

- Supplemental Information Disclosure Statement
- Form PTO-1449 listing sixty-three (63) reference
- Transmittal Letter

Respectfully submitted,

JOHN M. GYNN
Attorney for Applicant(s)
Registration No. 36,153
(801) 533-9800

JMG:sp

W:\15070\6.2\JPG0000001745V001.DOC

MAR 27 2006

RICK D. NYDEGGER
 BRENT P. LORIMER
 THOMAS R. VUKSINICK
 LARRY R. LAWCOCK
 JONATHAN W. RICHARDS
 DAVID R. WRIGHT
 JOHN C. STRINGHAM
 JOHN M. GUYNN
 CHARLES L. ROBERTS
 DANA L. TANGREN
 ERIC L. MASCHOFF
 CHARLES J. VEVERKA
 ROBIN L. PHILLIPS
 RICHARD C. GILMORE *
 STERLING A. BRENNAN
 R. BURNS ISRAELSEN
 DAVID R. TODD
 DAVID B. DELLENBACH
 L. DAVID GRIFIN
 ADRIAN J. LEE
 FRASER D. REY
 CARL T. REED

WORKMAN | NYDEGGER

INTELLECTUAL PROPERTY ATTORNEYS

1000 EAGLE GATE TOWER
 60 EAST SOUTH TEMPLE
 SALT LAKE CITY, UTAH 84111
 TELEPHONE: (801) 533-9800
 FAX: (801) 328-1707
 WEBSITE: HTTP://WWW.WNLAW.COM

FILED VIA FACSIMILE

PATENT APPLICATION
Docket No. 15070.6.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

B. Ron Johnson

Serial No.: 10/816,571

Confirmation No.: 1232

Filed: April 1, 2004

For: ANTI-INFECTIVE COMPOSITIONS, METHODS
 AND SYSTEMS FOR TREATING PATHOGEN-
 INDUCED DISORDERED TISSUES

Examiner: Not yet known

Customer No.: 022913

TRANSMITTAL FOR SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Mail Stop AMENDMENT
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing and pursuant to 37 C.F.R. § 1.97 is a Supplemental Information Disclosure Statement.

Enclosed also are the following designated documents, as required under 37 C.F.R. §§ 1.97 and 1.98:

X Form PTO-1449 listing sixty-three (63) reference submitted for consideration.

* Admitted only in California
 § Admitted only in Virginia

Commissioner for Patents
Page 2

- X This Supplemental Information Disclosure Statement is being filed prior to the later of either three (3) months following the filing date or the mailing of a first Office Action. Accordingly, no materials other than those listed above are enclosed.
- X In the event that 37 C.F.R. § 1.97(c) applies and the Examiner is not satisfied that the Promptness Certification meets the requirements of 37 C.F.R. § 1.97(e), or in any other event remediable by a fee, please credit any over payment or charge any additional fees to Deposit Account No. 23-3178 of the undersigned.

Dated this 27th day of March 2006.

Respectfully submitted,



JOHN M. GYNN
Attorney for Applicant
Registration No. 36,153
Customer No. 022913

JMG:sp
W:\15070\6.2\USJP0000001746V001.doc

MAR 27 2006

FILED VIA FACSIMILE

PATENT APPLICATION
Docket No. 15070.6.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
)
	B. Ron Johnson)
)
Serial No.:	10/816,571) Art Unit
) 1614
Confirmation No.:	1232)
)
Filed:	April 1, 2004)
)
For:	ANTI-INFECTIVE COMPOSITIONS, METHODS)
	AND SYSTEMS FOR TREATING PATHOGEN-)
	INDUCED DISORDERED TISSUES)
)
Examiner:	Not yet known)
)
Customer No.:	022913)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22310-1450

Sir:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form PTO-1449 which contains a list of all patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). While no representation is made that any of these references may be "prior art" within the meaning of that term under 35 U.S.C. §§ 102 or 103, the enclosed list of references is disclosed so as to fully comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.


Commissioner for Patents
Page 2

Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney of record believes that the enclosed art is the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.

Because each of the cited references is either a U.S. patent or a published U.S. application and/or was previously cited in a parent application relied upon for priority under 35 U.S.C. § 120, Applicant is not required to provide copies of any of the cited references.

DATED this 27th day of March 2006.

Respectfully submitted,



JOHN M. GYNN
Attorney for Applicant
Registration No. 36,153
Customer No. 022913
(801) 533-9800

JMG:sp

W:\15070\6.2\SJP0000001747V001.doc

FILED VIA FACSIMILE

Form PTO-1449

Sheet 1 of 5

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Docket No.: 15070.6.2

Filing Date: April 1, 2004

Group: 1614

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUESSUPPLEMENTAL INFORMATION DISCLOSURE CITATIONS MADE BY APPLICANTU.S. Patent Documents

<u>Examiner Initial*</u>	<u>Patent Number</u>	<u>Issue Date</u>	<u>Name</u>	<u>Class</u>	<u>Sub Class</u>	<u>Filing Date</u>
___ 1	4,420,484	12/13/83	Gorman et al.	424	326	11/12/81
___ 2	4,464,398	08/07/84	Sheets et al.	424	329	08/11/81
___ 3	4,523,589	06/18/85	Krauser	128	203.27	12/22/83
___ 4	4,532,128	07/30/85	Sheldon et al.	424	78	09/17/84
___ 5	4,599,335	07/08/86	Rentzea et al.	514	255	07/31/85
___ 6	4,745,132	05/17/88	Swered et al.	514	634	07/31/86
___ 7	4,778,813	10/18/88	Fenyess et al.	514	357	01/30/85
___ 8	4,820,737	04/11/89	Schoenwald et al.	514	654	03/16/88
___ 9	4,870,108	09/26/89	Page	514	642	09/20/88
___ 10	4,898,888	02/06/90	Baldone	514	642	07/05/88
___ 11	4,902,720	02/20/90	Baldone	514	642	07/05/88
___ 12	4,914,132	04/03/90	Donofrio et al.	514	643	05/25/89
___ 13	4,923,899	05/08/90	Wachman et al.	514	642	06/23/88
___ 14	4,983,635	01/08/91	Martin	514	643	09/12/88
___ 15	4,994,199	02/19/91	Scardera et al.	252	106	04/16/90

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FILED VIA FACSIMILE

Form PTO-1449

Sheet 2 of 5

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Docket No.: 15070.6.2

Filing Date: April 1, 2004

Group: 1614

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

16	5,026,561	06/25/91	Bourbon et al.	424	673	09/20/88
17	5,030,659	07/09/91	Bansemir et al.	514	635	02/08/90
18	5,039,688	08/13/91	Lewis	514	358	04/14/89
19	5,124,359	06/23/92	Wachman et al.	514	642	08/27/91
20	5,158,766	10/27/92	Greenwald et al.	424	78.33	06/28/90
21	5,284,875	02/08/94	Martin	514	643	04/16/93
22	5,320,805	06/14/94	Kramer et al.	422	28	05/15/91
23	5,338,748	08/16/94	Wachman et al.	514	358	12/09/93
24	5,344,838	09/06/94	Wachman et al.	514	358	12/08/93
25	5,446,014	08/29/95	Schuppiser et al.	504	250	07/26/91
26	5,514,640	05/07/96	Jones et al.	504	158	09/19/94
27	5,516,758	05/14/96	Stevens et al.	514	12	12/23/93
28	5,531,984	07/02/96	Staats	424	78.07	08/08/94
29	5,753,711	05/19/98	Schwabe et al.	514	643	03/18/97
30	5,897,872	04/27/99	Picciano	424	434	11/12/97
31	5,922,693	07/13/99	Oldenhove	514	63	02/20/98
32	5,939,461	08/17/99	Siqueira	514	642	08/15/95
33	5,962,391	10/05/99	Oldenhove	510	369	08/04/97
34	5,968,986	10/19/99	Dyer	514	643	01/14/98

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FILED VIA FACSIMILE

Form PTO-1449

Sheet 3 of 5

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Docket No.: 15070.6.2

Filing Date: April 1, 2004

Group: 1614

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

35	5,994,383	11/30/99	Dyer et al.	514	390	11/18/97
36	5,997,893	12/07/99	Jampani et al.	424	405	01/20/98
37	6,013,677	01/11/00	Dyer	514	643	01/06/99
38	6,087,400	07/11/00	Dyer et al.	514	643	06/11/99
39	6,165,494	12/26/00	Picciano	424	434	04/07/00
40	6,171,611	01/09/01	Picciano	424	434	01/19/99
41	6,187,332	02/13/01	Gern et al.	424	434	06/14/99
42	6,248,343	06/19/01	Jampani et al.	424	405	12/13/99
43	6,329,353	12/11/01	Dalrymple et al.	514	77	11/11/99
44	6,342,537	01/29/02	Thomsen et al.	514	724	10/13/99
45	6,344,210	02/05/02	Fust	424	435	02/16/01
46	6,348,503	02/19/02	Squires	514	642	02/12/96
47	6,350,784	02/26/02	Squires	514	642	03/26/97
48	6,355,684	03/12/02	Squires	514	643	05/08/96
49	6,419,850	07/16/02	Rouleau	252	180	01/10/97
50	6,436,885	08/20/02	Biedermann et al.	510	131	12/15/00
51	6,441,045	08/27/02	Birnbaum	514	643	11/03/99
52	6,444,707	09/03/02	Lampe et al.	514	642	08/22/00
53	6,525,034	02/25/03	Dalrymple et al.	514	77	10/19/01

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FILED VIA FACSIMILE

Form PTO-1449

Sheet 4 of 5

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Docket No.: 15070.6.2

Filing Date: April 1, 2004

Group: 1614

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

54	2001/0007651	07/12/01	Fust	424	49	02/16/01
55	2002/0006961	01/17/02	Katz et al.	514	625	05/01/01
56	2002/0136768	09/26/02	Staats	424	484	11/13/01
57	2002/0151521	10/17/02	Burke et al.	514	54	07/11/01
58	2002/0161046	10/31/02	Konowalchuk et al.	514	557	12/06/01
59	2002/0165277	11/07/02	Konowalchuk et al.	514	557	02/28/01
60	2002/0165278	11/07/02	Konowalchuk et al.	514	557	12/06/01
61	2002/0188028	12/12/02	Johnson	514	643	07/22/02
62	2002/0197212	12/26/02	Osbakken et al.	424	45	07/09/02
63	2003/0013769	01/16/03	Mukkamala et al.	514	642	05/06/02

References Cited by Applicants

While the filing of Information Disclosure Statements is voluntary, the procedure is governed by the guidelines of Section 609 of the Manual of Patent Examining Procedure and 37 C.F.R. §§ 1.97 and 1.98. To be considered a proper Information Disclosure Statement, Form PTO-1449 shall be accompanied by a copy of each listed patent or publication or other item of information and a translation of the pertinent portions of foreign documents (if an existing translation is readily available to the applicant), an explanation of relevance of each reference not in the English language, and should be submitted in a timely manner as set out in MPEP Sec. 609.

Examiners will consider all citations submitted in conformance with 37 C.F.R. § 1.98 and MPEP Sec. 609 and place their initials adjacent the citations in the spaces provided on this form. Examiners will also initial citations not in conformance with the guidelines which may have been considered. A reference may be considered by the Examiner for any reason whether or not the citation is in full conformance with the guidelines. A line will be drawn through a citation if it is not in conformance with the guidelines AND has not been considered. A copy of the submitted

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FILED VIA FACSIMILE

Form PTO-1449

Sheet 5 of 5

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Docket No.: 15070.6.2

Filing Date: April 1, 2004

Group: 1614

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

form, as reviewed by the Examiner, will be returned to the applicant with the next communication. The original of the form will be entered into the application file.

Each citation initialed by the Examiner will be printed on the issued patent in the same manner as references cited by the Examiner on Form PTO-892.

The reference designations "A1," "A2," etc. (referring to Applicant's reference 1, Applicant's reference 2, etc.) will be used by the Examiner in the same manner as Examiner's reference designations "A," "B," "C," etc. on Office Action Form PTO-1142.

W:\15070\6.2\SJP0000001742V001.doc

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.